The US enteric softgel capsules market is poised for substantial expansion, driven by a growing preference for advanced oral drug delivery systems and increasing demand in the pharmaceutical and nutraceutical segments. The market, valued at 1,680 Million in 2025, is expected to exhibit robust CAGR through 2035. Continuous innovation in encapsulation technologies and rising consumer awareness regarding targeted supplement delivery underline the sector’s rapid evolution. Companies are investing in plant-based and starch-based alternatives to address both regulatory pressures and evolving patient preferences. The market is shaped by key vendors including Catalent Inc., Aenova Group, EuroCaps Ltd, Capsugel (Lonza Group), and Sirio Pharma, among others, with a strong focus on technological leadership and customer expansion strategies.
Latest Market Dynamics
Key Drivers
Increased prevalence of chronic diseases is fueling pharmaceutical applications for enteric softgel capsules. For example, Catalent Inc. has expanded its capacity to meet clinical and commercial volume for gastro-resistant drugs.
Shifting consumer preference towards plant-based and non-gelatin capsules, as seen with Lonza's introduction of new vegetarian enteric softgel solutions for the US market.
Key Trends
Technological advancements in encapsulation such as starch-based and HPMC-based enteric coatings. BASF SE has launched innovative capsule solutions aiming at enhanced acid resistance.
Rising demand for personalized nutrition and custom dosage forms, supported by Sirio Pharma’s new softgel customization platforms launched in 2024.
Key Opportunities
Expansion of online and retail pharmacy channels, with significant investments by Thermo Fisher Scientific Inc. in digital supply chain enhancements to streamline distribution.
R&D on bio-based or green manufacturing processes to reduce environmental impact, as demonstrated by Fuji Capsule Co., Ltd's launch of biodegradable capsule shells.
Key Challenges
Stringent regulatory requirements for enteric coatings and excipients pose barriers to rapid product launches. Captek Softgel International, Inc. is currently addressing multi-state compliance challenges.
Escalating raw material costs impacting profit margins, as experienced by Soft Gel Technologies, Inc., which recently reported increased input costs in their quarterly review.
Key Restraints
Market fragmentation with strong competition from generic alternatives, making it challenging for newcomers to gain share — highlighted by Now Health GroupInc.’s difficulties expanding beyond core customers.
Slow speed of regulatory approval for new capsule compositions and ingredients, affecting product launch timelines for companies like Aland (Jiangsu) Nutraceutical Co. Ltd.
US Enteric Softgel Capsules Market Share by Type, 2025
In 2025, gelatin-based softgel capsules continue to dominate the US market, reflecting a stronghold derived from their wide application in pharmaceuticals and cost-effective manufacturing. Non-gelatin (including plant-derived and starch-based) capsules are rapidly gaining market share, largely due to growing vegetarian and vegan consumer segments, and advances in encapsulation science. Animal-derived variants still have a presence, primarily in traditional therapeutic areas. Plant-derived options are often preferred for dietary supplements and nutraceuticals, aligning with consumer demand for clean-label products. The market landscape is increasingly diversified, with innovation in starch and hydrocolloid-based capsules supporting inclusivity for allergy-prone or specific-diet populations.
US Enteric Softgel Capsules Market Share by Application, 2025
Pharmaceutical applications represent the bulk of softgel capsule demand in the US, largely due to the critical need for targeted, gastro-resistant drug delivery. Nutraceuticals hold a significant and growing share, underpinned by consumer focus on preventive healthcare and wellness products. Cosmetics are becoming a promising segment, as softgel encapsulation is increasingly used in beauty supplements and skin health formulas. The food & beverage and chemical industries, while niche, are leveraging softgel delivery for precision dosing and protection of sensitive active ingredients. The diversity of applications reflects the broadening utility of enteric softgel technology across multiple consumer and industrial categories.
US Enteric Softgel Capsules Market Revenue (USD Million), 2020-2035
The US enteric softgel capsules market is projected to post steady revenue growth from 2020 through 2035. Driven by expanded pharmaceutical and nutraceutical applications, coupled with favorable regulatory shifts and new product launches, revenues are anticipated to reach 4,620 Million by 2035. Robust investment in technological developments, the integration of plant-based solutions, and new commercialization strategies are contributing to consistent year-on-year gains. The data illustrates a healthy upward trajectory, indicative of sustained demand and successful industry adaptation to evolving therapeutic and consumer needs.
US Enteric Softgel Capsules Market YOY (%) Growth, 2020-2035
Year-on-year growth rates for the US enteric softgel capsules market show robust performance between 2020 and 2025, with peak momentum following the COVID-19 period due to surging nutraceutical and pharmaceutical consumption. YOY growth moderates toward 2035 as the market matures but remains positive, reflecting ongoing innovation and incremental expansion into new application areas. The adoption of advanced encapsulation technologies and the penetration of plant-based products help sustain attractive YOY percentages, enabling market players to reinforce their competitive position.
US Enteric Softgel Capsules Market Share by Regions (%), 2025
Regional distribution of the US enteric softgel capsules market in 2025 points to dominance by the South and West regions, attributed to high population density, robust presence of pharma/nutraceutical manufacturing, and advanced healthcare infrastructure. The Midwest region is gaining prominence due to increasing contract manufacturing activity, while the Northeast remains stable with its established pharmaceutical base. Regional shifts are also associated with state-level regulatory environments and evolving healthcare expenditure patterns.
US Enteric Softgel Capsules Market Players Share (%), 2025
Top market participants in the US enteric softgel capsules industry are Catalent Inc., Aenova Group, and Capsugel (Lonza Group), collectively accounting for the majority of market share. Catalent leads the market through scale, technological leadership, and broad partnerships. Aenova and Lonza’s Capsugel both leverage strong R&D and manufacturing capabilities to capture commercial and clinical segments. Other notable players include Sirio Pharma and Soft Gel Technologies, Inc., focusing on specialized formulations and niche markets. This competitive environment accelerates innovation and product diversification.
US Enteric Softgel Capsules Market Buyers Share (%), 2025
Major buyers of enteric softgel capsules comprise large pharmaceutical manufacturers, representing the largest share due to consistent demand for prescription and OTC drug formulations. Nutraceutical brands account for a rising proportion as the wellness and supplement industry accelerates. Contract development and manufacturing organizations (CDMOs) increasingly use these capsules to address the needs of emerging health and wellness buyers, providing versatility for both new launches and established product lines. This buyer distribution underscores sustained demand diversification across healthcare and wellness industries.
June 2024: Lonza’s Capsugel announces new vegetarian enteric softgel line expansion in the US to meet demand for plant-based pharmaceuticals.
July 2024: Catalent Inc. inaugurates high-capacity enteric softgel production facility in Indiana, boosting US manufacturing footprint.
August 2024: Sirio Pharma introduces a customizable enteric softgel platform for US nutraceutical companies to speed up time-to-market.
July 2024: BASF SE unveils next-gen HPMC-based enteric coating technology designed for enhanced drug stability in acidic environments.
June 2024: Thermo Fisher Scientific Inc. digitizes its US softgel supply chain for improved traceability and on-demand distribution.
Frequently Asked Questions
About the Author
Lena
Senior Research Consultant
Lena is a Senior Research Consultant specializing in market research, industry analysis, and business consulting across Telecommunication. Lena brings a commercially grounded perspective to sectors shaped by changing demand, innovation, and competitive dynamics, helping turn complex market trends into clear strategic insights for business decision-makers. With 10+ years of experience across research, analytics, and strategic advisory roles, Lena has helped organizations translate data into actionable growth strategies.
